Showing results (391-400 of 447) with videos related to

Sort By:
Pageof 45
The Lancet. Oncology|February 16, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trialJanet E Brown, Kara-Louise Royle, Walter Gregory, et al.
Genome Research|November 24, 2006
Accurate and reliable high-throughput detection of copy number variation in the human genomeHeike Fiegler, Richard Redon, Dan Andrews, et al.
Journal for Immunotherapy of Cancer|January 5, 2023
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 studyJason Chesney, Karl D Lewis, Harriet Kluger, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2017
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group studyEmeline Colomba, Gwénaël Le Teuff, Tim Eisen, et al.
The New England Journal of Medicine|June 7, 2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutationPaul B Chapman, Axel Hauschild, Caroline Robert, et al.
The New England Journal of Medicine|February 20, 2019
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaRobert J Motzer, Konstantin Penkov, John Haanen, et al.
Journal for Immunotherapy of Cancer|August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalMario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
The Lancet. Oncology|February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A McArthur, Paul B Chapman, Caroline Robert, et al.
The New England Journal of Medicine|September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaRobert J Motzer, Bernard Escudier, David F McDermott, et al.
Contemporary Clinical Trials Communications|November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and reportAngela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
Pageof 45